SAVA
Cassava Sciences Inc
-13.96%
$29.88 - $25.71
Feb 7th 2023 - Mar 21st 2023
AVXL
Anavex Life Sciences Corporation
-22.55%
$11.75 - $9.10
Feb 7th 2023 - Mar 21st 2023
Mar, 17, 2023
$BIVI what a difference it can make to have a stro... See more
Dec, 8, 2022
But doesnt change the fact that we have a very saf... See more
Mar, 17, 2023
$BIVI what a difference it can make to have a strong ceo: Cuong Do (president & ceo): Former President of Samsung Global Strategy Group and former Chief Strategy Officer for Merck - expect the coming 14 days to be really exciting !!
Mar, 17, 2023
$BIVI what a difference it can make to have a strong ceo: Cuong Do (president & ceo): Former President of Samsung Global Strategy Group and former Chief Strategy Officer for Merck - expect the coming 14 days to be really exciting !!
Dec, 8, 2022
But doesnt change the fact that we have a very safe and effective drug for alz, much better than competitors with more favorable sub group data likely to follow soon.
Dec, 7, 2022
$AVXL patients and special interest groups will come to Anavex wanting Blarcamesine! !
Dec, 7, 2022
Sub group analysis for 50 mg dosing is remarkable.
Dec, 3, 2022
I think certainly the patient groups will be very interested.
Dec, 3, 2022
Do not forget they met all endpoints for the 2 groups COMBINED!
Dec, 3, 2022
$AVXL importantly there a so-called superresponders in the blacarmesine treatment group, they improved in cognition score and these are 84% more than observed without that treatment.
Dec, 3, 2022
Patient advocate groups will push for approval! !
Nov, 7, 2022
And these posters are not child’s play they’re very detailed - they pack a lot of information onto one poster so a small group of people must have the results.
Oct, 20, 2022
What a group, a round of applause in order for the guys/gals who helped make this happen.